Uterine fibroids are the most common benign tumors of the female reproductive system, and the average age of patients is about 30-50 years old. They often manifest clinically as menstrual changes, abdominal masses and symptoms of occupational pressure such as difficulty in urination, urinary frequency and urgency, and constipation, which bring heavy physical and psychological burdens to patients. In the past, the treatment methods of uterine tumor mainly include drug therapy and surgery. Uterine artery embolization (UAE) was first used in 1970, and was initially applied to stop postpartum hemorrhage, devascularize tumors and treat vascular malformations with good results. In 1994, UAE was first introduced as an adjunct to surgical treatment of uterine fibroids in order to achieve myoma revascularization and reduce intraoperative bleeding, but it was unexpectedly found that uterine fibroids shrank significantly after UAE treatment, which aroused widespread interest among medical doctors in various countries. In 1995, UAE was firstly considered as an alternative to hysterectomy for the treatment of uterine fibroids, which could reduce excessive menstruation caused by fibroids, relieve anemia symptoms, and reduce the size of the uterus and fibroids to achieve the purpose of replacing surgery. In 1997 and 1998, Ravina’s group reported a larger number of cases in which uterine embolization was successfully performed in patients with symptomatic fibroids and recurrence after myomectomy. Subsequent reports in the literature from radiologists and obstetricians and gynecologists in France, the United States, Canada, and Japan have further confirmed the feasibility and utility of this treatment. By the end of 1999, more than 8,000 cases of this procedure were performed worldwide. However, the research and clinical application of UAE for uterine fibroids in China started late, but has recently gained attention.